“We are delighted that Dr. Majhail is joining Sarah Cannon and will work alongside our teams to foster an increased collaboration across our six U.S. and three U.K. blood cancer programs,†said Fred LeMaistre, MD, senior vice president of market operations and physician-in-chief of blood cancers at Sarah Cannon.
In this role, Dr. Majhail will work on expanding the Sarah Cannon Transplant and Cellular Therapy Network Centers of Excellence and increasing patient access to cellular and transplant therapies in surrounding communities. He will also serve as program medical director for the Sarah Cannon Transplant and Cellular Therapy program at Centennial Medical Center in Nashville, Tennessee.
Prior to joining Sarah Cannon, Dr. Majhail served as director of the Blood and Marrow Transplant Program at Cleveland Clinic, vice chair for the department of hematology and medical oncology, and professor of medicine at Cleveland Clinic Lerner College of Medicine. Additionally, he is a former president of the American Society for Transplantation and Cellular Therapy. Dr. Majhail’s research has focused on the prevention and management of early and late complications of hematopoietic cell transplantation as well as health policy issues such as disparities in health care, quality of care, survivorship, and economic issues related to transplantation and cellular therapy.
Source: Sarah Cannon press release, June 22, 2021.